A detailed history of Nichols & Pratt Advisers LLP transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Nichols & Pratt Advisers LLP holds 12,895 shares of BMY stock, worth $750,875. This represents 0.04% of its overall portfolio holdings.

Number of Shares
12,895
Previous 12,895 -0.0%
Holding current value
$750,875
Previous $535,000 24.67%
% of portfolio
0.04%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023

BUY
$57.89 - $64.73 $98,123 - $109,717
1,695 Added 15.13%
12,895 $748,000
Q2 2023

Aug 02, 2023

BUY
$63.71 - $70.74 $6,371 - $7,073
100 Added 0.9%
11,200 $716,000
Q1 2023

May 03, 2023

SELL
$65.71 - $74.53 $8,936 - $10,136
-136 Reduced 1.21%
11,100 $769,000
Q4 2022

Feb 03, 2023

SELL
$68.48 - $81.09 $9,518 - $11,271
-139 Reduced 1.22%
11,236 $808,000
Q3 2022

Nov 01, 2022

BUY
$0.13 - $76.84 $35 - $21,131
275 Added 2.48%
11,375 $808,000
Q1 2021

May 11, 2021

BUY
$59.34 - $66.74 $23,736 - $26,695
400 Added 3.74%
11,100 $701,000
Q4 2020

Feb 08, 2021

SELL
$57.74 - $65.43 $28,870 - $32,715
-500 Reduced 4.46%
10,700 $664,000
Q2 2020

Aug 10, 2020

SELL
$54.82 - $64.09 $6,030 - $7,049
-110 Reduced 0.97%
11,200 $659,000
Q1 2020

Apr 24, 2020

BUY
$46.4 - $67.43 $5,104 - $7,417
110 Added 0.98%
11,310 $631,000
Q4 2019

Feb 07, 2020

SELL
$49.21 - $64.19 $24,605 - $32,095
-500 Reduced 4.27%
11,200 $719,000
Q3 2019

Nov 07, 2019

SELL
$42.77 - $50.71 $2,224 - $2,636
-52 Reduced 0.44%
11,700 $594,000
Q1 2019

Apr 30, 2019

BUY
$45.12 - $53.8 $2,346 - $2,797
52 Added 0.44%
11,752 $561,000
Q2 2017

Aug 08, 2017

BUY
N/A
11,700
11,700 $652,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Nichols & Pratt Advisers LLP Portfolio

Follow Nichols & Pratt Advisers LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nichols & Pratt Advisers LLP , based on Form 13F filings with the SEC.

News

Stay updated on Nichols & Pratt Advisers LLP with notifications on news.